Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

FSD Pharma Inc C.HUGE

Alternate Symbol(s):  HUGE

Healthcare Cannabis
FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company’s two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company’s Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.


CSE:HUGE - Post by User

FSD Pharma Inc > Multiple Sclerosis Drugs Market Size , FSD has a MS drug
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Post by JensLenson May 31, 2022 9:49am
89 Views
Post# 34719687

Multiple Sclerosis Drugs Market Size , FSD has a MS drug

Multiple Sclerosis Drugs Market Size , FSD has a MS drug

Multiple Sclerosis Drugs Market Size & Trends 2022 - 2028 [CAGR 3.9%] | Industry Share, Growth by Fortune Business Insights

According to Fortune Business Insights, the global Multiple Sclerosis Drugs Market size is projected to reach USD 33.17 billion in 2029, at CAGR of 3.9% during forecast period; Increasing R&D in Neurology to Boost Market Growth: Fortune Business InsightsTM


Multiple Sclerosis Drugs Market Size & Trends 2022 - 2028 (globenewswire.com)
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities